Medtronic plc(MDT)Earnings, Financials & Key Ratios

MDT•NYSE

$77.79

$99.73B mkt cap·21.5× P/E·Price updated May 6, 2026

SectorHealthcare IndustryMedical Devices Sub-IndustryCardiovascular and heart rhythm devices

AboutMedtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.Show more

Revenue$33.54B+3.6%
EBITDA$8.82B+13.2%
Net Income$4.66B+26.8%
EPS (Diluted)3.61+30.8%
Gross Margin65.32%
EBITDA Margin26.29%+9.2%
Operating Margin17.76%+11.7%
Net Margin13.9%+22.4%
ROE9.45%+31.2%
ROIC6.01%+15.7%
Debt/Equity0.59+19.1%
Interest Coverage8.17+14.2%

Analysis→Technical→

MDT Key Insights

Medtronic plc (MDT) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Dividend Aristocrat: 36 years of consecutive increases
✓FCF machine: 15.5% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Healthy dividend yield of 3.6%
✓Share count reduced 3.0% through buybacks
✓Healthy 5Y average net margin of 13.0%

✗Weaknesses

No significant weaknesses identified

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

MDT Price & Volume

Medtronic plc (MDT) stock price & volume — 10-year historical chart

Loading chart...

MDT Growth Metrics

Medtronic plc (MDT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years5.17%

5 Years3.01%

3 Years1.91%

TTM6.88%

Profit CAGR

10 Years5.71%

5 Years-0.54%

3 Years-2.56%

TTM8.31%

EPS CAGR

10 Years4.12%

5 Years0.39%

3 Years-1.08%

TTM9.12%

Return on Capital

10 Years6.65%

5 Years6.65%

3 Years6.92%

Last Year7.54%

MDT Recent Earnings

Medtronic plc (MDT) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 12/12 qtrs (100%)●Beat Revenue 11/12 qtrs (92%)

Q1 2026Latest

Feb 17, 2026

EPS

$1.36

Est $1.34

+1.5%

Revenue

$9.0B

Est $8.9B

+1.2%

Q4 2025

Nov 18, 2025

EPS

$1.36

Est $1.31

+3.8%

Revenue

$9.0B

Est $8.9B

+1.1%

Q3 2025

Aug 19, 2025

EPS

$1.26

Est $1.23

+2.4%

Revenue

$8.6B

Est $8.4B

+2.4%

Q2 2025

May 21, 2025

EPS

$1.62

Est $1.58

+2.5%

Revenue

$8.9B

Est $8.8B

+1.2%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q1 2026Latest	Feb 17, 2026	$1.36vs $1.34+1.5%	$9.0Bvs $8.9B+1.2%
Q4 2025	Nov 18, 2025	$1.36vs $1.31+3.8%	$9.0Bvs $8.9B+1.1%
Q3 2025	Aug 19, 2025	$1.26vs $1.23+2.4%	$8.6Bvs $8.4B+2.4%
Q2 2025	May 21, 2025	$1.62vs $1.58+2.5%	$8.9Bvs $8.8B+1.2%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	FCF Yield	Debt / Equity
ABTAbbott LaboratoriesDirect Competitor	151.59B	87.18	11.41	4.59%	31.88%	27.26%	4.19%	0.32
BSXBoston Scientific CorporationDirect Competitor	83.2B	55.98	28.86	19.87%	14.4%	12.4%	4.4%	0.51
EWEdwards Lifesciences CorporationDirect Competitor	47.8B	82.91	45.31	11.55%	17.64%	10.35%	2.79%	0.07
SYKStryker CorporationDirect Competitor	113.08B	295.25	35.15	11.16%	12.92%	15.04%	3.79%	0.66
ZBHZimmer Biomet Holdings, Inc.Direct Competitor	16.25B	83.01	23.38	7.2%	9.05%	5.77%	9.06%	0.59
BDXBecton, Dickinson and CompanyDirect Competitor	52.23B	144.17	24.73	8.23%	8.01%	6.93%	5.11%	0.76
ISRGIntuitive Surgical, Inc.Product Competitor	160.32B	451.38	57.35	20.51%	28.15%	16.89%	1.55%	0.02
GMEDGlobus Medical, Inc.Product Competitor	12.18B	90.03	22.97	16.65%	18.3%	12.4%	4.84%	0.03

Compare MDT vs Peers

Medtronic plc (MDT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ABT

Most directly comparable listed peer for MDT.

Scale Benchmark

vs JNJ

Larger-name benchmark to compare MDT against a more recognizable public peer.

Peer Set

Compare Top 5

vs ABT, BSX, EW, SYK

MDT Income Statement

Medtronic plc (MDT) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Apr'17	Apr'18	Apr'19	Apr'20	Apr'21	Apr'22	Apr'23	Apr'24	Apr'25	TTM
Sales/Revenue	29.71B	29.95B	30.56B	28.91B	30.12B	31.69B	31.23B	32.36B	33.54B	35.48B
Revenue Growth %	3.04%	0.82%	2.02%	-5.38%	4.16%	5.21%	-1.45%	3.64%	3.62%	6.88%
Cost of Goods Sold	9.29B	9.07B	9.15B	9.42B	10.48B	10.14B	10.72B	11.22B	11.63B	13.5B
COGS % of Revenue	31.28%	30.27%	29.96%	32.59%	34.81%	32.02%	34.33%	34.66%	34.68%	-
Gross Profit	20.42B▲ 0%	20.89B▲ 2.3%	21.4B▲ 2.5%	19.49B▼ 8.9%	19.63B▲ 0.7%	21.54B▲ 9.7%	20.51B▼ 4.8%	21.15B▲ 3.1%	21.91B▲ 3.6%	21.98B▲ 0%
Gross Margin %	68.72%	69.73%	70.04%	67.41%	65.19%	67.98%	65.67%	65.34%	65.32%	61.95%
Gross Profit Growth %	3.68%	2.3%	2.47%	-8.94%	0.74%	9.71%	-4.8%	3.12%	3.58%	-
Operating Expenses	15.03B	14.25B	15.13B	14.7B	15.15B	15.79B	15.02B	16B	15.95B	15.64B
OpEx % of Revenue	50.6%	47.56%	49.53%	50.84%	50.3%	49.83%	48.11%	49.45%	47.56%	-
Selling, General & Admin	10.02B	10.24B	10.42B	10.11B	10.15B	10.29B	10.41B	10.74B	10.85B	11.45B
SG&A % of Revenue	33.72%	34.18%	34.09%	34.96%	33.7%	32.48%	33.35%	33.17%	32.35%	-
Research & Development	2.19B	2.26B	2.33B	2.33B	2.49B	2.75B	2.7B	2.73B	2.73B	2.89B
R&D % of Revenue	7.38%	7.53%	7.63%	8.06%	8.28%	8.67%	8.63%	8.45%	8.15%	-
Other Operating Expenses	2.82B	1.75B	2.39B	2.26B	2.51B	2.75B	1.91B	2.53B	2.37B	1000K
Operating Income	5.38B▲ 0%	6.64B▲ 23.4%	6.27B▼ 5.6%	4.79B▼ 23.6%	4.48B▼ 6.4%	5.75B▲ 28.3%	5.49B▼ 4.6%	5.14B▼ 6.2%	5.96B▲ 15.8%	6.34B▲ 0%
Operating Margin %	18.12%	22.17%	20.51%	16.57%	14.89%	18.15%	17.56%	15.89%	17.76%	17.86%
Operating Income Growth %	0.41%	23.35%	-5.6%	-23.56%	-6.41%	28.28%	-4.64%	-6.22%	15.77%	-
EBITDA	8.3B	9.28B	8.93B	7.45B	7.19B	8.46B	8.18B	7.79B	8.82B	9.42B
EBITDA Margin %	27.94%	31%	29.21%	25.78%	23.86%	26.7%	26.2%	24.07%	26.29%	26.55%
EBITDA Growth %	1.45%	11.86%	-3.85%	-16.5%	-3.6%	17.71%	-3.27%	-4.78%	13.16%	14.24%
D&A (Non-Cash Add-back)	2.92B	2.64B	2.66B	2.66B	2.7B	2.71B	2.7B	2.65B	2.86B	3.08B
EBIT	5.7B	6.82B	6.64B	5.15B	4.82B	6.07B	6B	5.56B	6.36B	6.46B
Net Interest Income	-1.09B	-1.15B	-1.44B	-1.09B	-925M	-553M	-636M	-719M	-729M	-558M
Interest Income	0	0	0	0	0	0	0	0	0	154M
Interest Expense	1.09B	1.15B	1.44B	1.09B	925M	553M	636M	719M	729M	712M
Other Income/Expense	-781M	-965M	-1.07B	-736M	-589M	-235M	-121M	-307M	-327M	-776M
Pretax Income	4.6B▲ 0%	5.67B▲ 23.3%	5.2B▼ 8.4%	4.05B▼ 22.0%	3.9B▼ 3.9%	5.52B▲ 41.6%	5.36B▼ 2.8%	4.84B▼ 9.8%	5.63B▲ 16.4%	5.56B▲ 0%
Pretax Margin %	15.49%	18.95%	17.01%	14.02%	12.93%	17.41%	17.18%	14.95%	16.78%	15.68%
Income Tax	578M	2.58B	547M	-751M	265M	456M	1.58B	1.13B	936M	923M
Effective Tax Rate %	12.56%	45.46%	10.53%	-18.52%	6.8%	8.27%	29.46%	23.42%	16.63%	16.59%
Net Income	4.03B▲ 0%	3.1B▼ 22.9%	4.63B▲ 49.2%	4.79B▲ 3.4%	3.61B▼ 24.7%	5.04B▲ 39.7%	3.76B▼ 25.4%	3.68B▼ 2.2%	4.66B▲ 26.8%	4.61B▲ 0%
Net Margin %	13.56%	10.36%	15.16%	16.56%	11.97%	15.9%	12.03%	11.36%	13.9%	13%
Net Income Growth %	13.85%	-22.94%	49.19%	3.41%	-24.7%	39.74%	-25.42%	-2.18%	26.82%	8.31%
Net Income (Continuing)	4.02B	3.1B	4.65B	4.81B	3.63B	5.06B	3.78B	3.7B	4.69B	4.64B
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	122M	102M	121M	135M	174M	171M	182M	206M	232M	0
EPS (Diluted)	2.89▲ 0%	2.27▼ 21.5%	3.41▲ 50.2%	3.54▲ 3.8%	2.66▼ 24.9%	3.73▲ 40.2%	2.82▼ 24.4%	2.76▼ 2.1%	3.61▲ 30.8%	3.58▲ 0%
EPS Growth %	16.53%	-21.45%	50.22%	3.81%	-24.86%	40.23%	-24.4%	-2.13%	30.8%	9.12%
EPS (Basic)	2.92	2.29	3.44	3.57	2.68	3.75	2.83	2.77	3.63	-
Diluted Shares Outstanding	1.39B	1.37B	1.36B	1.35B	1.35B	1.35B	1.33B	1.33B	1.29B	1.29B
Basic Shares Outstanding	1.38B	1.36B	1.35B	1.34B	1.34B	1.34B	1.33B	1.33B	1.29B	1.28B
Dividend Payout Ratio	58.99%	80.35%	58.15%	60.43%	86.52%	67.14%	96.22%	99.73%	76.98%	-

MDT Balance Sheet

Medtronic plc (MDT) balance sheet — assets, liabilities & shareholders' equity

Line item	Apr'17	Apr'18	Apr'19	Apr'20	Apr'21	Apr'22	Apr'23	Apr'24	Apr'25	TTM
Total Current Assets	24.87B	22.98B	21.97B	22.03B	22.55B	23.06B	21.68B	21.93B	23.81B	4.04B
Cash & Short-Term Investments	13.71B	11.23B	9.85B	10.95B	10.82B	10.57B	7.96B	8.01B	8.96B	4.76B
Cash Only	4.97B	3.67B	4.39B	4.14B	3.59B	3.71B	1.54B	1.28B	2.22B	4.76B
Short-Term Investments	8.74B	7.56B	5.46B	6.81B	7.22B	6.86B	6.42B	6.72B	6.75B	0
Accounts Receivable	5.59B	5.99B	6.22B	4.64B	5.46B	5.55B	6B	6.13B	6.51B	87M
Days Sales Outstanding	68.69	72.96	74.32	58.64	66.2	63.94	70.11	69.11	70.91	49.51
Inventory	3.34B	3.58B	3.75B	4.23B	4.31B	4.62B	5.29B	5.22B	5.48B	-803M
Days Inventory Outstanding	131.09	144.08	149.63	163.79	150.17	166.08	180.24	169.78	171.83	70.67
Other Current Assets	2.24B	2.19B	2.14B	2.21B	1.96B	2.32B	2.42B	2.58B	2.86B	0
Total Non-Current Assets	74.98B	68.41B	67.73B	68.66B	70.53B	67.92B	69.27B	68.05B	67.86B	-1.42B
Property, Plant & Equipment	4.36B	4.6B	4.67B	4.83B	5.22B	5.41B	5.57B	6.13B	6.84B	-1.42B
Fixed Asset Turnover	6.81x	6.51x	6.54x	5.99x	5.77x	5.85x	5.61x	5.28x	4.91x	11.75x
Goodwill	38.52B	39.54B	39.96B	39.84B	41.96B	40.5B	41.42B	40.99B	41.74B	0
Intangible Assets	23.41B	21.72B	20.56B	19.06B	17.74B	15.59B	14.84B	13.22B	11.67B	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	8.7B	2.54B	2.53B	4.93B	5.61B	6.41B	7.44B	7.7B	7.62B	30.25B
Total Assets	99.82B▲ 0%	91.39B▼ 8.4%	89.69B▼ 1.9%	90.69B▲ 1.1%	93.08B▲ 2.6%	90.98B▼ 2.3%	90.95B▼ 0.0%	89.98B▼ 1.1%	91.68B▲ 1.9%	2.63B▲ 0%
Asset Turnover	0.30x	0.33x	0.34x	0.32x	0.32x	0.35x	0.34x	0.36x	0.37x	0.51x
Asset Growth %	0.27%	-8.44%	-1.86%	1.11%	2.64%	-2.26%	-0.04%	-1.06%	1.89%	-92.38%
Total Current Liabilities	14.26B	10.08B	8.47B	10.37B	8.51B	12.39B	9.05B	10.79B	12.88B	1.6B
Accounts Payable	1.55B	1.63B	1.95B	2B	2.11B	2.28B	2.66B	2.41B	2.45B	0
Days Payables Outstanding	61.07	65.54	77.86	77.31	73.33	81.89	90.65	78.43	76.85	51.27
Short-Term Debt	7.52B	2.06B	832M	2.77B	2M	3.74B	13M	1.09B	2.87B	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	1.94B	1.99B	2.19B	2.1B	2.48B	2.12B	1.95B	2.38B	2.52B	1.6B
Current Ratio	1.74x	2.28x	2.59x	2.13x	2.65x	1.86x	2.39x	2.03x	1.85x	1.85x
Quick Ratio	1.51x	1.92x	2.15x	1.72x	2.14x	1.49x	1.81x	1.55x	1.42x	1.42x
Cash Conversion Cycle	138.71	151.5	146.09	145.12	143.04	148.13	159.7	160.46	165.89	68.92
Total Non-Current Liabilities	35.18B	30.49B	31.01B	29.45B	32.97B	25.86B	30.23B	28.77B	30.55B	0
Long-Term Debt	25.86B	23.68B	24.47B	21.98B	26.32B	20.32B	24.29B	23.88B	25.59B	0
Capital Lease Obligations	23M	21M	10M	45M	62M	56M	57M	55M	52M	158M
Deferred Tax Liabilities	2.98B	1.42B	1.28B	1.17B	1.03B	884M	708M	515M	403M	1.21B
Other Non-Current Liabilities	6.4B	5.36B	5.25B	6.26B	5.57B	4.61B	5.18B	4.33B	4.5B	13.61B
Total Liabilities	49.4B	40.57B	39.48B	39.82B	41.48B	38.26B	39.28B	39.56B	43.42B	0
Total Debt	33.4B	25.76B	25.32B	24.8B	26.39B	24.11B	24.36B	25.02B	28.52B	0
Net Debt	28.43B	22.09B	20.92B	20.66B	22.8B	20.4B	22.82B	23.74B	26.3B	-4.76B
Debt / Equity	0.66x	0.51x	0.50x	0.49x	0.51x	0.46x	0.47x	0.50x	0.59x	0.59x
Debt / EBITDA	4.02x	2.77x	2.84x	3.33x	3.67x	2.85x	2.98x	3.21x	3.23x	0.00x
Net Debt / EBITDA	3.43x	2.38x	2.34x	2.77x	3.17x	2.41x	2.79x	3.05x	2.98x	2.98x
Interest Coverage	4.92x	5.79x	4.34x	4.39x	4.85x	10.40x	8.62x	7.15x	8.17x	9.08x
Total Equity	50.42B▲ 0%	50.82B▲ 0.8%	50.21B▼ 1.2%	50.87B▲ 1.3%	51.6B▲ 1.4%	52.72B▲ 2.2%	51.66B▼ 2.0%	50.42B▼ 2.4%	48.26B▼ 4.3%	0▲ 0%
Equity Growth %	-2.72%	0.81%	-1.2%	1.31%	1.44%	2.17%	-2%	-2.41%	-4.29%	-104.06%
Book Value per Share	36.23	37.15	36.99	37.65	38.11	39.01	38.76	37.90	37.41	37.41
Total Shareholders' Equity	50.29B	50.72B	50.09B	50.74B	51.43B	52.55B	51.48B	50.21B	48.02B	0
Common Stock	0	0	0	0	0	0	0	0	0	-181M
Retained Earnings	23.36B	24.38B	26.27B	28.13B	28.59B	30.25B	30.39B	30.4B	31.48B	0
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-2.61B	-1.79B	-2.71B	-3.56B	-3.48B	-2.27B	-3.5B	-3.32B	-4.28B	0
Minority Interest	122M	102M	121M	135M	174M	171M	182M	206M	232M	0

MDT Cash Flow Statement

Medtronic plc (MDT) cash flow — operating, investing & free cash flow history

Line item	Apr'17	Apr'18	Apr'19	Apr'20	Apr'21	Apr'22	Apr'23	Apr'24	Apr'25	TTM
Cash from Operations	6.88B	4.68B	7.01B	7.23B	6.24B	7.35B	6.04B	6.79B	7.04B	7.04B
Operating CF Margin %	23.16%	15.64%	22.93%	25.02%	20.72%	23.18%	19.34%	20.97%	21%	-
Operating CF Growth %	31.85%	-31.92%	49.59%	3.24%	-13.74%	17.72%	-17.79%	12.39%	3.79%	4.58%
Net Income	4.02B	3.1B	4.65B	4.81B	3.63B	5.06B	3.78B	3.68B	4.69B	4.61B
Depreciation & Amortization	2.92B	2.64B	2.66B	2.66B	2.7B	2.71B	2.7B	2.65B	2.86B	2.33B
Stock-Based Compensation	348M	344M	290M	297M	344M	359M	355M	393M	429M	357M
Deferred Taxes	-459M	-919M	-304M	-1.31B	-422M	-604M	-226M	-508M	-316M	-176M
Other Non-Cash Items	-89M	-307M	792M	722M	687M	711M	396M	1.06B	433M	1.56B
Working Capital Changes	139M	-173M	-1.08B	61M	-701M	-889M	-967M	-484M	-1.05B	-1.42B
Change in Receivables	-75M	-275M	-581M	1.29B	-761M	-477M	-576M	-391M	-433M	-162M
Change in Inventory	-227M	-192M	-274M	-577M	78M	-560M	-939M	-139M	-292M	-617M
Change in Payables	356M	65M	399M	-44M	531M	213M	696M	391M	209M	289M
Cash from Investing	-1.57B	5.86B	-774M	-3.2B	-2.87B	-1.66B	-3.49B	-2.37B	-1.94B	-2.51B
Capital Expenditures	-1.25B	-1.07B	-1.13B	-1.21B	-1.35B	-1.37B	-1.46B	-1.59B	-1.86B	-1.88B
CapEx % of Revenue	4.22%	3.57%	3.71%	4.2%	4.5%	4.32%	4.67%	4.9%	5.54%	-
Acquisitions	-1.32B	5.92B	-1.83B	-488M	-994M	-91M	-1.87B	-211M	-98M	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	22M	-22M	36M	-37M	-54M	-10M	4M	-261M	-249M	-149M
Cash from Financing	-3.28B	-11.95B	-5.43B	-4.2B	-4.14B	-5.34B	-4.96B	-4.45B	-4.36B	-5.21B
Debt Issued (Net)	2.18B	-7.6B	-867M	-559M	-570M	-1M	-598M	1.07B	2.14B	-1.01B
Equity Issued (Net)	-1000K	-1000K	-1000K	-1000K	-1000K	-1000K	-1000K	-1000K	-1000K	-2M
Dividends Paid	-2.38B	-2.49B	-2.69B	-2.89B	-3.12B	-3.38B	-3.62B	-3.67B	-3.59B	-3.63B
Share Repurchases	-3.54B	-2.17B	-2.88B	-1.33B	-652M	-2.54B	-645M	-2.14B	-3.23B	-874M
Other Financing	26M	-94M	14M	581M	206M	163M	-101M	-3M	-184M	-221M
Net Change in Cash	2.09B▲ 0%	-1.3B▼ 162.1%	724M▲ 155.8%	-253M▼ 134.9%	-547M▼ 116.2%	121M▲ 122.1%	-2.17B▼ 1894.2%	-259M▲ 88.1%	934M▲ 460.6%	-3.79B▲ 0%
Free Cash Flow	5.63B▲ 0%	3.62B▼ 35.7%	5.87B▲ 62.4%	6.02B▲ 2.5%	4.88B▼ 18.9%	5.98B▲ 22.4%	4.58B▼ 23.4%	5.2B▲ 13.5%	5.18B▼ 0.3%	5.41B▲ 0%
FCF Margin %	18.94%	12.07%	19.22%	20.82%	16.22%	18.87%	14.67%	16.07%	15.46%	15.24%
FCF Growth %	34.85%	-35.73%	62.42%	2.52%	-18.87%	22.37%	-23.39%	13.54%	-0.29%	-1.06%
FCF per Share	4.04	2.64	4.33	4.46	3.61	4.42	3.44	3.91	4.02	4.02
FCF Conversion (FCF/Net Income)	1.71x	1.51x	1.51x	1.51x	1.73x	1.46x	1.61x	1.85x	1.51x	1.17x
Interest Paid	1.13B	1.15B	973M	643M	582M	540M	606M	826M	762M	737M
Taxes Paid	1.03B	2.54B	1.56B	878M	1.25B	996M	1.55B	1.62B	1.82B	-121M

MDT Key Ratios

Medtronic plc (MDT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Return on Equity (ROE)	7.88%	6.13%	9.17%	9.48%	7.04%	9.66%	7.2%	7.2%	9.45%	12.71%
Return on Invested Capital (ROIC)	5.08%	6.56%	6.53%	5.04%	4.61%	5.85%	5.57%	5.19%	6.01%	6.01%
Gross Margin	68.72%	69.73%	70.04%	67.41%	65.19%	67.98%	65.67%	65.34%	65.32%	61.95%
Net Margin	13.56%	10.36%	15.16%	16.56%	11.97%	15.9%	12.03%	11.36%	13.9%	13%
Debt / Equity	0.66x	0.51x	0.50x	0.49x	0.51x	0.46x	0.47x	0.50x	0.59x	0.59x
Interest Coverage	4.92x	5.79x	4.34x	4.39x	4.85x	10.40x	8.62x	7.15x	8.17x	9.08x
FCF Conversion	1.71x	1.51x	1.51x	1.51x	1.73x	1.46x	1.61x	1.85x	1.51x	1.17x
Revenue Growth	3.04%	0.82%	2.02%	-5.38%	4.16%	5.21%	-1.45%	3.64%	3.62%	6.88%

MDT SEC Filings & Documents

Medtronic plc (MDT) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Mar 24, 2026·SEC

Material company update

Feb 17, 2026·SEC

Material company update

Nov 18, 2025·SEC

10-K Annual Reports

FY 2025

Jun 20, 2025·SEC

FY 2024

Jun 20, 2024·SEC

10-Q Quarterly Reports

FY 2026

Feb 24, 2026·SEC

FY 2025

Nov 25, 2025·SEC

FY 2025

Aug 26, 2025·SEC

MDT Frequently Asked Questions

Medtronic plc (MDT) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Medtronic plc (MDT) reported $35.48B in revenue for fiscal year 2025. This represents a 1536% increase from $2.17B in 1996.

Medtronic plc (MDT) grew revenue by 3.6% over the past year. Growth has been modest.

Yes, Medtronic plc (MDT) is profitable, generating $4.61B in net income for fiscal year 2025 (13.9% net margin).

Dividend & Returns

Yes, Medtronic plc (MDT) pays a dividend with a yield of 3.58%. This makes it attractive for income-focused investors.

Medtronic plc (MDT) has a return on equity (ROE) of 9.4%. This is below average, suggesting room for improvement.

Medtronic plc (MDT) generated $5.41B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More MDT

Medtronic plc (MDT) financial analysis — history, returns, DCA and operating performance tools

Full MDT Stock Analysis

Analyst verdict, bull/bear case, risk factors and peer comparison

→

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Medtronic plc(MDT)Earnings, Financials & Key Ratios

MDT Key Insights

✓Strengths

✗Weaknesses

MDT Price & Volume

MDT Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

MDT Recent Earnings

MDT Peer Comparison

Compare MDT vs Peers

vs ABT

vs JNJ

Compare Top 5

MDT Income Statement

MDT Balance Sheet

MDT Cash Flow Statement

MDT Key Ratios

MDT SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

MDT Frequently Asked Questions

Explore More MDT

Full MDT Stock Analysis

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation